On November 18, 2021, Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced the closing of its underwritten public offering of 10,062,500 shares of its common stock, which includes 1,312,500 shares sold pursuant to the exercise in full by the underwriters of the option to purchase additional shares, at a price to the public of $40.00 per share. Including the option exercise, the aggregate gross proceeds to Apellis were $402.5 million, before deducting underwriting discounts and commissions and expenses payable by Apellis. J.P. Morgan Securities LLC, Goldman Sachs & Co. LLC and Evercore Group L.L.C. acted as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated, Oppenheimer & Co. Inc. and Raymond James acted as lead managers for the offering.

The WilmerHale team advising Apellis Pharmaceuticals in its public offering was led by Stuart Falber and Craig Hilts, and included Katharine Patterson.